Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 8/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9470027 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL9637838 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL10043031 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL25227184 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL1096268 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL25077516 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL15070695 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL25227181 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL385333 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL3368533 | 0.99 | USP2 (0.45) | USP2TLR2CETPCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | UNIV CALIFORNIA (US) | 2025-01-09 | — | — | US | disclosed |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4469061-A2 | ANTIVIRAL PRODRUGS, INTERMEDIATE- AND LONG-ACTING FORMULATIONS AND METHODS | The Regents of the University of California (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591377-A | Antiviral prodrugs, intermediate and long acting formulations and methods | 加利福尼亚大学董事会 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024159117-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-02 | — | — | WO | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2022020793-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-27 | — | — | WO | disclosed |
| US-8076520-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7709464-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-02-05 | — | — | US | disclosed |
| US-7351428-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20040213836-A1 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20030053978-A1 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2003-03-20 | — | — | US | disclosed |
| US-20020090383-A1 | Compounds which increase the survival duration of liposomes | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-11 | — | — | US | disclosed |
| US-6413543-B1 | DRUG DELIVERY | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040213836-A1 | Phosphatidyl oligoglycerols | PHOSPHO1, SGMS1, SGMS2 | USP2 2036/4885TLR2 1775/4885CETP 120/4885 |
| US-20030053978-A1 | Phosphatidyl oligoglycerols | PHOSPHO1, SGMS1, SGMS2 | USP2 2339/4885TLR2 2025/4885CETP 150/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | USP2 1686/4885TLR2 1430/4885CETP 469/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | USP2 4298/4885TLR2 3182/4885CETP 85/4885 |
| US-20020090383-A1 | Compounds which increase the survival duration of liposomes | VEGFA, MCL1, LIPA | USP2 1898/4885TLR2 2810/4885CETP 76/4885 |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | USP2 2163/4885TLR2 1912/4885CETP 114/4885 |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | MTAP, SARS1, RNGTT | USP2 2515/4885TLR2 4377/4885CETP 651/4885 |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | USP2 2163/4885TLR2 1912/4885CETP 114/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | USP2 4298/4885TLR2 3182/4885CETP 85/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | USP2 1637/4885TLR2 953/4885CETP 360/4885 |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | USP2 2515/4885TLR2 4377/4885CETP 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.